Abstract
Acromegaly is a rare chronic, systemic disorder caused by excessive growth hormone (GH) secretion from a somatotroph pituitary adenoma. GH hypersecretion leads to overproduction of insulin-like growth factor-1 (IGF-1), which contributes to the somatic overgrowth, physical disfigurement, onset of multiple systemic comorbidities, reduced quality of life (QoL) and premature mortality of uncontrolled patients. Somatostatin receptor ligands, dopamine agonists and a GH receptor antagonist are currently available for medical therapy of acromegaly. The main aim of treatment is biochemical normalisation, defined as age-normalised serum IGF-1 values and random GH levels <1.0 μg/L. However, there is an increasing evidence suggesting that achieving biochemical control does not always decrease the burden of disease-related comorbidities and/or improve patients’ QoL. This lack of correlation between biochemical and clinical control can be due to both disease duration (late diagnosis) or to the peculiarity of a given comorbidity. Herein we conducted ad hoc literature searches in order to find the most recent and relevant reports on biochemical and clinical disease control during medical treatment of acromegaly. Particularly, we analyse and describe the relationship between biochemical, as well as clinical disease control in patients with acromegaly receiving medical therapy, with a focus on comorbidities and QoL. In conclusion, we found that current literature data seem to indicate that clinical disease control (besides biochemical control), encompassing clinical signs and symptoms, comorbidities and QoL, emerge as a primary focus of acromegaly patient management.
Similar content being viewed by others
References
Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355(24):2558–73. https://doi.org/10.1056/NEJMra062453.
Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933–51. https://doi.org/10.1210/jc.2014-2700.
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–52. https://doi.org/10.1210/er.2002-0022.
Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89–95. https://doi.org/10.1530/EJE-08-0267.
Casanueva FF, Barkan AL, Buchfelder M, Klibanski A, Laws ER, Loeffler JS, et al. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a pituitary society statement. Pituitary. 2017;20(5):489–98. https://doi.org/10.1007/s11102-017-0838-2.
Abreu A, Tovar AP, Castellanos R, Valenzuela A, Giraldo CM, Pinedo AC, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary. 2016;19(4):448–57. https://doi.org/10.1007/s11102-016-0725-2.
Lotti F, Rochira V, Pivonello R, Santi D, Galdiero M, Maseroli E, et al. Erectile dysfunction is common among men with acromegaly and is associated with morbidities related to the disease. J Sex Med. 2015;12(5):1184–93. https://doi.org/10.1111/jsm.12859.
Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, et al. Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10(4):243–8. https://doi.org/10.1038/nrendo.2014.21.
Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552–61. https://doi.org/10.1038/s41574-018-0058-5.
Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, Pena L, Lugo G, Sangiao-Alvarellos S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. 2013;8(4):e61523. https://doi.org/10.1371/journal.pone.0061523.
Bacigaluppi S, Gatto F, Anania P, Bragazzi NL, Rossi DC, Benvegnu G, et al. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center. Endocrine. 2016;51(3):524–33. https://doi.org/10.1007/s12020-015-0619-5.
McKeage K. Pasireotide in acromegaly: a review. Drugs. 2015;75(9):1039–48. https://doi.org/10.1007/s40265-015-0413-y.
Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825–33. https://doi.org/10.1210/jc.2013-3757.
Schilbach K, Strasburger CJ, Bidlingmaier M. Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary. 2017;20(1):33–45. https://doi.org/10.1007/s11102-017-0792-z.
Alexopoulou O, Bex M, Abs R, T'Sjoen G, Velkeniers B, Maiter D. Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab. 2008;93(4):1324–30. https://doi.org/10.1210/jc.2007-2104.
Schofl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B, et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German acromegaly register. Eur J Endocrinol. 2013;168(1):39–47. https://doi.org/10.1530/EJE-12-0602.
Machado EO, Taboada GF, Neto LV, van Haute FR, Correa LL, Balarini GA, et al. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Hormon IGF Res. 2008;18(5):389–93. https://doi.org/10.1016/j.ghir.2008.02.001.
Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009;94(2):523–7. https://doi.org/10.1210/jc.2008-1371.
Geraedts VJ, Andela CD, Stalla GK, Pereira AM, van Furth WR, Sievers C et al. Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. Front Endocrinol (Lausanne). 2017;8:40. https://doi.org/10.3389/fendo.2017.00040.
Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667–74. https://doi.org/10.1210/jc.2003-031199.
Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, et al. Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry. Eur J Endocrinol. 2017;176(5):645–55. https://doi.org/10.1530/EJE-16-1064.
Giustina A, Arnaldi G, Bogazzi F, Cannavo S, Colao A, De Marinis L, et al. Pegvisomant in acromegaly: an update. J Endocrinol Investig. 2017;40(6):577–89. https://doi.org/10.1007/s40618-017-0614-1.
Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol. 2007;67(1):65–70. https://doi.org/10.1111/j.1365-2265.2007.02836.x.
Christiansen Arlien-Soborg M, Trolle C, Alvarson E, Baek A, Dal J. Otto Lunde Jorgensen J. biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients. Endocrine. 2017;56(3):589–94. https://doi.org/10.1007/s12020-017-1258-9.
Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, et al. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol. 2004;61(1):138–44. https://doi.org/10.1111/j.1365-2265.2004.02064.x.
Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–73. https://doi.org/10.1210/jc.2005-0260.
Colao A, Auriemma RS, Pivonello R, Kasuki L, Gadelha MR. Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary. 2016;19(3):235–47. https://doi.org/10.1007/s11102-015-0684-z.
Puig DM. Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol. 2015;83(1):3–14. https://doi.org/10.1111/cen.12731.
Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 1996;81(6):2356–62. https://doi.org/10.1210/jcem.81.6.8964877.
Lindsay JR, McConnell EM, Hunter SJ, McCance DR, Sheridan B, Atkinson AB. Poor responses to a test dose of subcutaneous octreotide predict the need for adjuvant therapy to achieve 'safe' growth hormone levels. Pituitary. 2004;7(3):139–44. https://doi.org/10.1007/s11102-005-1756-2.
de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol. 2005;153(1):67–71. https://doi.org/10.1530/eje.1.01935.
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Hormon IGF Res. 2005;15(3):200–6. https://doi.org/10.1016/j.ghir.2005.02.007.
Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE, Wass JA. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol. 2005;62(3):282–8. https://doi.org/10.1111/j.1365-2265.2004.02191.x.
Halperin I, Nicolau J, Casamitjana R, Sesmilo G, Serra-Prat M, Palomera E, et al. A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res. 2008;40(6):422–6. https://doi.org/10.1055/s-2008-1065339.
Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327–35. https://doi.org/10.1210/jc.2010-2443.
Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374–8. https://doi.org/10.1210/jcem.83.2.4556.
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171–7. https://doi.org/10.1056/NEJM200004203421604.
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754–9.
Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99(3):791–9. https://doi.org/10.1210/jc.2013-2480.
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2(11):875–84. https://doi.org/10.1016/S2213-8587(14)70169-X.
Lim DS, Fleseriu M. The role of combination medical therapy in the treatment of acromegaly. Pituitary. 2017;20(1):136–48. https://doi.org/10.1007/s11102-016-0737-y.
Christofides EA. Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly. Patient Prefer Adherence. 2016;10:1217–25. https://doi.org/10.2147/PPA.S102302.
Tolis G, Angelopoulos NG, Katounda E, Rombopoulos G, Kaltzidou V, Kaltsas D, et al. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs. Neuroendocrinology. 2006;83(3–4):249–57. https://doi.org/10.1159/000095535.
Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268–332. https://doi.org/10.1210/er.2018-00115.
Yedinak CG, Fleseriu M. Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study. Endocrine. 2014;46(3):585–93. https://doi.org/10.1007/s12020-013-0106-9.
Yang LP, Keating GM. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2010;70(13):1745–69. https://doi.org/10.2165/11204510-000000000-00000.
Burness CB, Dhillon S, Keam SJ. Lanreotide autogel((R)): a review of its use in the treatment of patients with acromegaly. Drugs. 2014;74(14):1673–91. https://doi.org/10.1007/s40265-014-0283-8.
Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, Ferone D. Somatostatin receptor ligands in the treatment of acromegaly. Pituitary. 2017;20(1):100–8. https://doi.org/10.1007/s11102-017-0791-0.
Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly. Pituitary. 2017;20(1):129–35. https://doi.org/10.1007/s11102-016-0753-y.
Lesen E, Granfeldt D, Houchard A, Dinet J, Berthon A, Olsson DS, et al. Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol. 2017;176(2):203–12. https://doi.org/10.1530/EJE-16-0623.
Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K, Sahnoun-Fathallah M, et al. Acromegaly at diagnosis in 3173 patients from the Liege acromegaly survey (LAS) database. Endocr Relat Cancer. 2017;24(10):505–18. https://doi.org/10.1530/ERC-17-0253.
Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R, et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary. 2017;20(1):46–62. https://doi.org/10.1007/s11102-017-0797-7.
Sardella C, Cappellani D, Urbani C, Manetti L, Marconcini G, Tomisti L, et al. Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly. Eur J Endocrinol. 2016;175(5):443–53. https://doi.org/10.1530/EJE-16-0562.
Topaloglu O, Sayki Arslan M, Turak O, Ginis Z, Sahin M, Cebeci M, et al. Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules. Clin Endocrinol. 2014;80(5):726–34. https://doi.org/10.1111/cen.12356.
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab. 2000;85(9):3132–40. https://doi.org/10.1210/jcem.85.9.6782.
Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S, et al. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Investig. 2002;25(11):971–6. https://doi.org/10.1007/BF03344070.
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, et al. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol. 2003;58(2):169–76.
Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007;92(5):1743–7. https://doi.org/10.1210/jc.2006-2547.
Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab. 2007;92(2):476–82. https://doi.org/10.1210/jc.2006-1587.
Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, et al. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab. 2008;93(7):2639–46. https://doi.org/10.1210/jc.2008-0299.
De Marinis L, Bianchi A, Mazziotti G, Mettimano M, Milardi D, Fusco A, et al. The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. Pituitary. 2008;11(1):13–20. https://doi.org/10.1007/s11102-007-0062-6.
Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R. Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab. 2009;94(10):3746–56. https://doi.org/10.1210/jc.2009-0941.
Bogazzi F, Lombardi M, Strata E, Aquaro G, Lombardi M, Urbani C, et al. Effects of somatostatin analogues on acromegalic cardiomyopathy: results from a prospective study using cardiac magnetic resonance. J Endocrinol Investig. 2010;33(2):103–8. https://doi.org/10.1007/BF03346562.
Comunello A, Dassie F, Martini C, De Carlo E, Mioni R, Battocchio M, et al. Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues. Pituitary. 2015;18(4):525–34. https://doi.org/10.1007/s11102-014-0605-6.
Auriemma RS, Grasso LF, Galdiero M, Galderisi M, Pivonello C, Simeoli C, et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine. 2017;55(3):872–84. https://doi.org/10.1007/s12020-016-0995-5.
Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol. 2011;75(2):220–5. https://doi.org/10.1111/j.1365-2265.2011.04019.x.
Akdeniz B, Gedik A, Turan O, Ozpelit E, Ikiz AO, Itil O, et al. Evaluation of left ventricular diastolic function according to new criteria and determinants in acromegaly. Int Heart J. 2012;53(5):299–305.
Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab. 2013;98(3):1040–50. https://doi.org/10.1210/jc.2012-3072.
Kuhn E, Maione L, Bouchachi A, Roziere M, Salenave S, Brailly-Tabard S, et al. Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur J Endocrinol. 2015;173(5):693–702. https://doi.org/10.1530/EJE-15-0500.
dos Santos Silva CM, Gottlieb I, Volschan I, Kasuki L, Warszawski L, Balarini Lima GA, et al. Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J Clin Endocrinol Metab. 2015;100(12):4447–55. https://doi.org/10.1210/jc.2015-2675.
Carmichael JD, Broder MS, Cherepanov D, Chang E, Mamelak A, Said Q, et al. The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr Disord. 2017;17(1):15. https://doi.org/10.1186/s12902-017-0166-6.
Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, et al. Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab. 2004;89(1):71–5. https://doi.org/10.1210/jc.2003-030849.
van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, et al. Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Hormon IGF Res. 2006;16(2):101–7. https://doi.org/10.1016/j.ghir.2006.02.002.
Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, et al. High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab. 2003;88(7):3196–201. https://doi.org/10.1210/jc.2002-021099.
Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, et al. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13(1):51–6.
Maffei P, Martini C, Milanesi A, Corfini A, Mioni R, de Carlo E, et al. Late potentials and ventricular arrhythmias in acromegaly. Int J Cardiol. 2005;104(2):197–203. https://doi.org/10.1016/j.ijcard.2004.12.010.
Warszawski L, Kasuki L, Sa R, Dos Santos Silva CM, Volschan I, Gottlieb I, et al. Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naive acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary. 2016;19(6):582–9. https://doi.org/10.1007/s11102-016-0749-7.
Unubol M, Eryilmaz U, Guney E, Ture M, Akgullu C. QT dispersion in patients with acromegaly. Endocrine. 2013;43(2):419–23. https://doi.org/10.1007/s12020-012-9828-3.
Fatti LM, Scacchi M, Lavezzi E, Pecori Giraldi F, De Martin M, Toja P, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol. 2006;65(5):626–30. https://doi.org/10.1111/j.1365-2265.2006.02639.x.
Orosz A, Csajbok E, Czekus C, Gavaller H, Magony S, Valkusz Z, et al. Increased short-term beat-to-beat variability of QT interval in patients with acromegaly. PLoS One. 2015;10(4):e0125639. https://doi.org/10.1371/journal.pone.0125639.
Ragonese M, Alibrandi A, Di Bella G, Salamone I, Puglisi S, Cotta OR, et al. Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction. Endocrine. 2014;47(1):206–12. https://doi.org/10.1007/s12020-013-0115-8.
Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, et al. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab. 2007;92(11):4271–7. https://doi.org/10.1210/jc.2007-1213.
Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, Garcia-Dominguez A, Reza-Albarran AA, et al. The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab. 2016;101(11):3997–4004. https://doi.org/10.1210/jc.2016-1937.
Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol. 2006;154(3):467–77. https://doi.org/10.1530/eje.1.02112.
Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, et al. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment. Clin Endocrinol. 2008;69(4):613–20. https://doi.org/10.1111/j.1365-2265.2008.03258.x.
Sardella C, Urbani C, Lombardi M, Nuzzo A, Manetti L, Lupi I, et al. The beneficial effect of acromegaly control on blood pressure values in normotensive patients. Clin Endocrinol. 2014;81(4):573–81. https://doi.org/10.1111/cen.12455.
Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism. 1990;39(2):133–7.
Muniyappa R, Walsh MF, Rangi JS, Zayas RM, Standley PR, Ram JL, et al. Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production. Life Sci. 1997;61(9):925–31.
Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS. Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int. 1994;45(2):598–604.
Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, et al. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab. 2010;95(8):3648–56. https://doi.org/10.1210/jc.2009-2570.
Puder JJ, Nilavar S, Post KD, Freda PU. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. J Clin Endocrinol Metab. 2005;90(4):1972–8. https://doi.org/10.1210/jc.2004-2009.
Colao A. Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary. 2012;15(1):50–8. https://doi.org/10.1007/s11102-011-0318-z.
Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, et al. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab. 2007;92(2):673–80. https://doi.org/10.1210/jc.2006-1578.
Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo S, De Marinis L, et al. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Investig. 2014;37(10):1017–30. https://doi.org/10.1007/s40618-014-0146-x.
Samson SL. Management of Hyperglycemia in patients with acromegaly treated with Pasireotide LAR. Drugs. 2016;76(13):1235–43. https://doi.org/10.1007/s40265-016-0615-y.
Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5):1500–8. https://doi.org/10.1210/jc.2008-2332.
Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E, et al. Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. 2018;103:2089–99. https://doi.org/10.1210/jc.2017-02566.
Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684–91. https://doi.org/10.1210/jc.2005-0331.
Jonas C, Maiter D, Alexopoulou O. Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm Metab Res. 2016;48(5):299–305. https://doi.org/10.1055/s-0035-1569277.
Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011;14(3):284–94. https://doi.org/10.1007/s11102-011-0310-7.
Colao A, Marzullo P, Vallone G, Marino V, Annecchino M, Ferone D, et al. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab. 1998;83(6):2121–5. https://doi.org/10.1210/jcem.83.6.4865.
Colao A, Marzullo P, Vallone G, Giaccio A, Ferone D, Rossi E, et al. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol. 1999;51(5):611–8.
Colao A, Cannavo S, Marzullo P, Pivonello R, Squadrito S, Vallone G, et al. Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly. Eur J Endocrinol. 2003;148(1):31–8.
Claessen KM, Ramautar SR, Pereira AM, Romijn JA, Kroon HM, Kloppenburg M, et al. Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary. 2014;17(1):44–52. https://doi.org/10.1007/s11102-013-0464-6.
Claessen KM, Ramautar SR, Pereira AM, Smit JW, Roelfsema F, Romijn JA, et al. Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. Eur J Endocrinol. 2012;167(2):235–44. https://doi.org/10.1530/EJE-12-0147.
Claessen KM, Mazziotti G, Biermasz NR, Giustina A. Bone and joint disorders in acromegaly. Neuroendocrinology. 2016;103(1):86–95. https://doi.org/10.1159/000375450.
Mazziotti G, Biagioli E, Maffezzoni F, Spinello M, Serra V, Maroldi R, et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2015;100(2):384–94. https://doi.org/10.1210/jc.2014-2937.
Mazziotti G, Frara S, Giustina A. Pituitary diseases and bone. Endocr Rev. 2018;39(4):440–88. https://doi.org/10.1210/er.2018-00005.
Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res. 2005;20(10):1837–44. https://doi.org/10.1359/JBMR.050603.
Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29(5):535–59. https://doi.org/10.1210/er.2007-0036.
Godang K, Olarescu NC, Bollerslev J, Heck A. Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study. Eur J Endocrinol. 2016;175(2):155–64. https://doi.org/10.1530/EJE-16-0340.
Tagliafico A, Resmini E, Nizzo R, Bianchi F, Minuto F, Ferone D, et al. Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly. J Clin Endocrinol Metab. 2008;93(3):905–9. https://doi.org/10.1210/jc.2007-1719.
Resmini E, Tagliafico A, Nizzo R, Bianchi F, Minuto F, Derchi L, et al. Ultrasound of peripheral nerves in acromegaly: changes at 1-year follow-up. Clin Endocrinol. 2009;71(2):220–5. https://doi.org/10.1111/j.1365-2265.2008.03468.x.
Weiss V, Sonka K, Pretl M, Dostalova S, Klozar J, Rambousek P, et al. Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Investig. 2000;23(8):515–9. https://doi.org/10.1007/BF03343767.
Garcia-Rio F, Pino JM, Diez JJ, Ruiz A, Villasante C, Villamor J. Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion. Am J Respir Crit Care Med. 2001;164(5):852–7. https://doi.org/10.1164/ajrccm.164.5.2005059.
Davi MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol. 2008;159(5):533–40. https://doi.org/10.1530/EJE-08-0442.
Akkoyunlu ME, Ilhan MM, Bayram M, Tasan E, Yakar F, Ozcelik HK, et al. Does hormonal control obviate positive airway pressure therapy in acromegaly with sleep-disordered breathing? Respir Med. 2013;107(11):1803–9. https://doi.org/10.1016/j.rmed.2013.08.043.
Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol. 2006;155(6):831–7. https://doi.org/10.1530/eje.1.02292.
Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol. 2008;158(3):305–10. https://doi.org/10.1530/EJE-07-0697.
T'Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R. Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol. 2007;157(4):411–7. https://doi.org/10.1530/EJE-07-0356.
Kyriakakis N, Lynch J, Gilbey SG, Webb SM, Murray RD. Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: results from a 5-years prospective study. Clin Endocrinol. 2017;86(6):806–15. https://doi.org/10.1111/cen.13331.
Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008;93(10):3853–9. https://doi.org/10.1210/jc.2008-0669.
Paisley AN, Rowles SV, Roberts ME, Webb SM, Badia X, Prieto L, et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol. 2007;67(3):358–62. https://doi.org/10.1111/j.1365-2265.2007.02891.x.
Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, et al. Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol (Oxf). 2005;63(1):103–10. https://doi.org/10.1111/j.1365-2265.2005.02307.x.
Vandeva S, Yaneva M, Natchev E, Elenkova A, Kalinov K, Zacharieva S. Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by acromegaly quality of life (AcroQoL) questionnaire. Endocrine. 2015;49(3):774–82. https://doi.org/10.1007/s12020-014-0521-6.
Webb SM, Crespo I, Santos A, Resmini E, Aulinas A, Valassi E. MANAGEMENT OF ENDOCRINE DISEASE: quality of life tools for the management of pituitary disease. Eur J Endocrinol. 2017;177(1):R13–26. https://doi.org/10.1530/EJE-17-0041.
Imran SA, Tiemensma J, Kaiser SM, Vallis M, Doucette S, Abidi E, et al. Morphometric changes correlate with poor psychological outcomes in patients with acromegaly. Eur J Endocrinol. 2016;174(1):41–50. https://doi.org/10.1530/EJE-15-0888.
Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab. 2005;90(5):2731–9. https://doi.org/10.1210/jc.2004-2297.
Geraedts VJ, Dimopoulou C, Auer M, Schopohl J, Stalla GK, Sievers C. Health Outcomes in Acromegaly: Depression and Anxiety are Promising Targets for Improving Reduced Quality of Life. Front Endocrinol (Lausanne). 2014;5:229. https://doi.org/10.3389/fendo.2014.00229.
Tiemensma J, Pereira AM, Romijn JA, Broadbent E, Biermasz NR, Kaptein AA. Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test. Eur J Endocrinol. 2015;172(5):583–93. https://doi.org/10.1530/EJE-14-0996.
Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR. Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. J Clin Endocrinol Metab. 2011;96(11):3550–8. https://doi.org/10.1210/jc.2011-1645.
Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004;114(3):349–56. https://doi.org/10.1172/JCI19933.
Pokrajac A, Frystyk J, Flyvbjerg A, Trainer PJ. Pituitary-independent effect of octreotide on IGF1 generation. Eur J Endocrinol. 2009;160(4):543–8. https://doi.org/10.1530/EJE-08-0822.
Neggers SJ, Kopchick JJ, Jorgensen JO, van der Lely AJ. Hypothesis: extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol. 2011;164(1):11–6. https://doi.org/10.1530/EJE-10-0969.
Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK et al. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest. 2009;32(11):924–933. https://doi.org/10.3275/6723 10.1007/BF03345774.
Kepicoglu H, Hatipoglu E, Bulut I, Darici E, Hizli N, Kadioglu P. Impact of treatment satisfaction on quality of life of patients with acromegaly. Pituitary. 2014;17(6):557–63. https://doi.org/10.1007/s11102-013-0544-7.
van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, et al. Coadministration of lanreotide autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011;164(3):325–33. https://doi.org/10.1530/EJE-10-0867.
Madsen M, Poulsen PL, Orskov H, Moller N, Jorgensen JO. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab. 2011;96(8):2405–13. https://doi.org/10.1210/jc.2011-0654.
Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005;90(10):5627–31. https://doi.org/10.1210/jc.2005-0531.
De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, et al. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary. 2007;10(3):227–32. https://doi.org/10.1007/s11102-007-0037-7.
Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, et al. Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol. 2013;169(1):99–108. https://doi.org/10.1530/EJE-13-0032.
Brue T, Castinetti F. The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis. 2016;11(1):135. https://doi.org/10.1186/s13023-016-0516-x.
Mercado M, Gonzalez B, Vargas G, Ramirez C. de los Monteros AL, Sosa E et al. successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014;99(12):4438–46. https://doi.org/10.1210/jc.2014-2670.
Acknowledgments
Financial support for medical editorial assistance was provided by Novartis Pharma AG. We thank Tracy Harrison and Georgii Filatov, Springer Healthcare Communications for the medical writing assistance.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflicts of interest/financial disclosures
FG has been a speaker for Novartis and has participated on advisory boards of Novartis, AMCo Ltd. and IONIS Pharmaceuticals. DF has been a speaker for and participated on advisory boards and received research grants from Novartis and Ipsen. The other Authors have no conflicts of interest to declare.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gatto, F., Campana, C., Cocchiara, F. et al. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Disord 20, 365–381 (2019). https://doi.org/10.1007/s11154-019-09506-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11154-019-09506-y